Diener, Knoll, Ratge, Langer and Wissei: Urinary excretion of alanine aminopeptidase and N-acetyl-/3-D-glucosaminidase 615 J. Clin. Chem. Clin. Biochem. Vol. 20,1982, pp. 615-619 Urinary Excretion of Alanine Aminopeptidase and N-Acetyl-/3-Z)-Glucosaminidase During Sequential Combination Chemotherapy 1 ) (Received December 14, 1981/April 16,1982 Summary: The urinary excretion of alanine aminopeptidase (EC 3.4.11.2) and N-acetyl-0-.D-glucosaminidase (EC 3.2.1.30) was determined in 23 patients with testicular cancer during sequential combination chemotherapy with vinblastine/bleomycin and doxorubicin/cis-platinum. Increases in enzyme excretion were more often noticed during therapy with vinblastine/bleomycin than with doxorubicin/cis-platinum. Moreover, the rises during vinblastine/ bleomycin therapy were more pronounced. The enzyme activities varied from the normal ränge up to the 14-fold of the upper limit of the normal ränge. With few exceptions, enzyme excretions returned to normal or slightly elevated values before the subsequent course. No renal insufficiency could be detected with the commonly used parameters of renal function such äs serum creatinine concentrations and creatinine clearance values, which were determined at irregulär intervals.
Introduction
serum creat uii ne ^ 4 f 5). Therefore changes in urinary Determination of urinary enzyme excretion has become enzyme Output are an early sign of alteration or damage a recognized aid in diagnosis and monitoring of drug to the kidney tubules. It is not always possible to decide nephrotoxicity (1, 2) . Increases in enzyme activities have if there is a direct or secondary effect of the drug on the been demonstiated before elevations in serum urea and tubule. Nephrotoxicity is one of the major complications during *) This study was supported by the Robert Bosch Stiftung, therapy with the cytostatic drug cis-platinum. In preStuttgart (F.R.G.)
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öfter therapy with cis-platinum -alone or in combination with other drugs -the urinary enzyme activities were elevated (3, 4, 6, 7) . In these studies the patients received in most cases a single high dose of cis-platinum during one therapy course. One aim of this trial was the examination of the response of the enzymes during the administration of cis-platinum in a low dose once a day for five days. Cis-platinum was part of a sequential combination chemotherapy with vinblastine/bleomycin and doxorubicin/cis-platinum. All patients, who received this therapy, had testicular cancer. For our investigations we chose the brush border enzyme alanine aminopeptidase (EC 3.4.11.2) and the lysosomal enzyme N-acetyl-0-£>-ghicosaminidase (EC 3.2.1.30). The simultaneous determination of the two enzymes -each of different origin -might permit conclusions on the localization of renal damage or on the different mechanism of action of the drugs in the same part of the tubules. Furthermore, it should be possible to show whether enzymuriasif at all detectable -are reversible. Another point of this investigation was a comparison of the enzyme excretion during courses with vinblastine/bleomycin before and after the administration of doxorubicin/cis-platinum in order to establish an eventual influence of doxorubicin/cis-platinum on the enzyme excretion duririg the therapy with vinblastine/bleomycin.
Methods
The enzyme activities were determined in 3-h urine samples which were collected from 7 to 10 a.m. The constant sampling time should eliminate influences of any circadian rhythm (8) . Storage in a refrigerator at 6 °C proved to be the best method of maintaining constant enzyme activities (3, 9) . The determinations of alanine aminopeptidase and N-acetyl-0-Z)-glucosaminidase were carried out äs described in detail by Diener et al. 0.19-1.06 U/mmol creatinine -median: 0.46 U/mmol creatinine. As urinary enzyme activities -expressed äs units per mmol of urinary creatinine -had been determined at different temperatures they were standardized by dividing by the upper Knut of the normal ränge. Creatinine was measured in serum and urine by a modified Jaffe method (10) . During sönie therapy cqurses with doxorubicin/cis-platinum the urinary protein patterns were determined with the aid of high performance gel permeation chromatography (11).
Patients and therapy 23 patients with testicular cancer were entered in this study. The average age was 30 years, ranging from 16-47 years. Jn some cases the carcinomas were disseminated. 17 patients had nonseminomatous carcinomas. Six patients had nonseminomatous carcinomas with seminomatous elements. After orchiectomy and in some cases retroperitoneal lymphadenectomy some patients received an adjuvant therapy and the others a remissionin du crion therapy. The treatment consists of a sequential combination chemotherapy with vinblastine/bleomycin and doxorubicin/cis-platinum according to Scheuten et al. (12) 
Results

Vinblastine/bleomycin (regimen I)
Serum creatinine concentrations and creatinine clearance values -detennined at irregulär intervals -were within the reference ränge during therapy. The minimal enzyme excretioris at the begmning of the courses and the maximal excretioris during therapy äre shöwn in figure l. Only in four cases the pre-treatment values were elevated above the 2-fold of the upper limit of the normal ränge. During therapy the excretions of both enzymes increased. Iti 38% of the courses the älanine aminopeptidase values and in 48 % of the courses the N-acetyl-jfcDgjucosaminidase values were not higher than the 2-fold of the upper limit of the normal ränge (tab. 2). Alanine aminopeptidase excretion was elevated above the 6-fold of the upper limit during three courses (6%)i whereas N-acetyl-^jD-glucosäminidase excretion was higher than the 6-fold during eight courses (16%). In some patients the enzyme activities decreased during therapy. If the pre-treatment values were elevated, >the ex;cretion of both enzymes increased strongly during the courses. figure 3, the pre-treatment values of the enzyme excretions were -with one exception -lower than the 2-fold of the upper limit of the normal ränge. In contrast to the courses with regimen I, the enzyme activities of alanine aminopeptidase and N-acetyl-/J-£>-glucosaminidase increased above the 2-fold of the upper limit in only approx. 20% of the courses (tab. 2). In one course, the maximal value was higher than the 6-fold of the upper limit of the normal ränge. In this patient, the pre-treatment value was elevated.
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max. max. Increases were noticed partieularly in those patients who had raised enzyme activities during treatment with vinblastine/bleomyein (tab. 3). The urinary protein pattern was deterrnined for a single course from each of five patients. There was a good cofrelation between enzyme excretion and protem'pattem. No pathological proteinuria could be detected whenever the enzyme excretion was normal. However, in the course of other investigations with patients receiving a single high dose of cis-platinüm (100 mg/m-) this relationship could not be established. These patients showed large interindividual differences in the excretion pattern of proteins during increased enzyme excretion.
Discussion
As shown in table 2, more iricreases in enzyme excretion could be seen during theräpy with vinblastine/bleomyein than during ädministration of doxorubicin/cis-platinum. In addition, the increases were more pronounced. Elevated enzyme excretions during therapy with vinblastine/bleomyein occurred before äs well äs after the courses with doxorubicin/cis-platinum. Thus an influence of the Jatter drug combination could almost completely be excluded. This coiiclusion is supported by the fact that the pre-treätment values of the courses with bleomycin following the Administration of doxorubicin/cis-platinum were within the normal ränge or only slightly increased. The four elevated pre-treatment values at the beginning of the therapy with vinblastine/bleomyein ( fig. 1 ) eöuld be seen in the two courses beföfe patients had received the first ädministration of doxorubicin/eis^platinum, The elevated enzyme activities at the beginning of the chemotherapy could be a result of the orchiectoiiiy, which had been made seven to 17 days before. Thus, several authors (13, 14) described increased uriiiary enzyme excretions äs a result of extrarenal causes, e.g, those occurring during and after operations. Thus, we dempnstrated elevated activities of both enzymes after ä gästric resection and a resection of ä carcinoma of the rectum, with enzyme excretion increasing up to the S^fold of the upper limit of the normal ränge (fig, 4) . A fiirther indication of a reduction of renal function before the first ädministration of cy tostatics shows the course of the enzyme excretiön of patient G during the reinissioninduction therapy. At the beginning of the first course, he had elevated values of alanine aminopepticlase (8-fold) and N-acetyl-j3-D-glucösaminidäse (3.5-föld) which increased during the course up to the 14rfpld (alanine aminopeptidase) and lÖ-foid:(N-acetyl-j3-£)-. gjucosaminidase) of the upper limit of the normal ränge. In all subsequent courses the maximal values of alanine aminopeptidase arid N-acetyl^/XgJucosamimdase activities were below the 2-fold of 1}ie upper limit of the jiormal ränge. A compärison between the exeretion pattern during ädministration of vinblastine/bleomyein and doxorubicin/cis-platinum in this investigation and the pattern during therapy with ds-platinum or aminoglycoside previously described (3) show that the course of the excretion of both enzymes during vinblastine/ bleomycin is similar to that during doxorubicin/cisplatinum or cis-platinum, respectively. The similar excretion patterns might be an indication of the same point of attack of the drugs. However, it must be mentioned that the exact mechanism of action of vinblastine and bleomycin remains to be investigated. Up to now it is not possible to decide whether the enzymurias were caused by a direct effect of the drugs on the tubular cells or by an extrarenaUy produced tubular damage. The problem of nephrotoxicity of vinblastine and bleomycin will have to be solved in animal experiments. As far äs permitted by the present studies, a cumulative nephrotoxic effect of vinblastine/ bleomycin on the subsequent courses was shown to be unlikely. With one exception ( fig. l ; patient H., course 2) the pre-treätment values of the following courses were within the normal ränge or only slightly elevated. The reasons for the normalization of the enzymurias might be due both to the distribution of the total dosis of bleomycin and cis-platinum on several days during simultaneous diuresis and the great time interval between the courses. Furthermore, the turnover of tubular epithelial cells might speed up the excretion of the drugs or their metabolites during the intervals. However, if a few days äfter the end of the course a treatment with antibiotics in the leukopenic phase were necessary, a cumulative nephrotoxic effect might occur. This specujation is supported by our own investigations (in preparation). During the administration of gentamicin and ticarcillin in the leukopenic phase a further strong increase of enzyme activities could be demonstrated. To sum up, tubular alterations -detected by enzymurias -were not only noticed in patients receiving the nephrotoxic drug cis-platinum but also in patients receiving vinblastine/bleomycin. Cumulative nephrotoxicity can normally not be observed if the time intervals between the courses are at least äs long äs in this plan of treatment.
